JNJ's esketamine meets depression endpoint

The Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ) said intranasal esketamine (formerly JNJ-54135419) met the primary endpoint in the Phase II SYNAPSE

Read the full 269 word article

User Sign In